: October 10, 2022; Expiration date: October 10, 2023 Learning Objectives: Upon completion of this activity, participants will be able to: • Integrate into professional practice the updates to the NCCN Guidelines for Survivorship • Describe the
Search Results
NCCN Guidelines® Insights: Survivorship, Version 1.2022
Featured Updates to the NCCN Guidelines
Tara Sanft, Andrew Day, Lindsay Peterson, M. Alma Rodriguez, Shannon Ansbaugh, Saro Armenian, K. Scott Baker, Tarah Ballinger, Gregory Broderick, Wendy Demark-Wahnefried, Kristin Dickinson, Nathan Paul Fairman, Debra L. Friedman, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Nazanin Khakpour, Divya Koura, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C.F. Moore, Natalie Moryl, Heather Neuman, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Chirayu Patel, William Pirl, Andrea Porpiglia, Kathryn J. Ruddy, Lidia Schapira, Lillie Shockney, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Eric H. Yang, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021
Featured Updates to the NCCN Guidelines
Nadeem R. Abu-Rustum, Catheryn M. Yashar, Kristin Bradley, Susana M. Campos, Junzo Chino, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Elisabeth Diver, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Robert Giuntoli II, Ernest Han, Brooke Howitt, Warner K. Huh, Jayanthi Lea, Andrea Mariani, David Mutch, Larissa Nekhlyudov, Mirna Podoll, Steven W. Remmenga, R. Kevin Reynolds, Ritu Salani, Rachel Sisodia, Pamela Soliman, Edward Tanner, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole R. McMillian, and Angela D. Motter
activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Uterine Neoplasms Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Uterine Neoplasms
Presented by: David S. Craig
Oncology [NCCN Guidelines] for Adult Cancer Pain,” Dr. Craig remarked ( Figure 1 ). “We tried to take a very comprehensive but simplified approach on what to do for genetic testing, who should be tested, and what we [should be] looking for.” Figure 1
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020
Featured Updates to the NCCN Guidelines
Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller, and Lenora A. Pluchino
be able to: Integrate into professional practice the updates to the NCCN Guidelines for Hematopoietic Growth Factors Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Hematopoietic Growth Factors
Presented by: Maria Alma Rodriguez
Practice Guidelines in Oncology (NCCN Guidelines) for Survivorship: Immunizations and Infections] is that we should review with our patients their immunization history and recommend that they update and receive any vaccines that they are missing and that
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020
Featured Updates to the NCCN Guidelines
Nadeem R. Abu-Rustum, Catheryn M. Yashar, Sarah Bean, Kristin Bradley, Susana M. Campos, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Robert Giuntoli II, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Rachel Sisodia, Todd Tillmanns, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole R. McMillian, and Angela D. Motter
to: Integrate into professional practice the updates to the NCCN Guidelines for Cervical Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Cervical Cancer Disclosure of Relevant Financial
Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Patrick F. Fogarty, Shuwei Gao, Julio Garcia-Aguilar, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Kimberly A. Jones, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Judy L. Smith, Gary C. Yee, and Anaadriana Zakarija
,106 patients hospitalized with adult neutropenic cancer showed that 2.7% to 12.1% of these patients, depending on the type of malignancy, experienced VTE during their first hospitalization. 1 These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
Featured Updates to the NCCN Guidelines
Natalie S. Callander, Muhamed Baljevic, Kehinde Adekola, Larry D. Anderson Jr, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Srinivas Devarakonda, Noura Elsedawy, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Michaela Liedtke, Thomas Martin, James Omel, Douglas Sborov, Kenneth Shain, Keith Stockerl-Goldstein, Donna Weber, Ryan A. Berardi, Rashmi Kumar, and Shaji K. Kumar
: January 10, 2022; Expiration date: January 10, 2023 Learning Objectives: Upon completion of this activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Multiple Myeloma Describe the
Presented by: William J. Gradishar
Professor of Breast Oncology, Northwestern University Feinberg School of Medicine; Director, Robert H. Lurie Comprehensive Cancer Center’s Maggie Daley Center for Women’s Cancer Care; and Chair of the NCCN Guidelines Panel for Breast Cancer, at the NCCN 2022
Ronald S. Walters
measures that would target such improvement. The measures identified focused on concordance with specific recommendations in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer ( Table 1 ) or timely access to and
